# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-100863
Filing Date
2022-09-16
Accepted
2022-09-16 16:36:54
Documents
7
Period of Report
2022-11-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2225310-1_def14a.htm | DEF 14A | 1048034
2 | GRAPHIC | lg_phibrocorp-4c.jpg | GRAPHIC | 43603
3 | GRAPHIC | sg_thomasdagger-bw.jpg | GRAPHIC | 11708
4 | GRAPHIC | tm2225310d1-bc_ceo4c.jpg | GRAPHIC | 136716
5 | GRAPHIC | tm2225310d1-fc_base4c.jpg | GRAPHIC | 38532
6 | GRAPHIC | tm2225310d1-px_animalbw.jpg | GRAPHIC | 626244
7 | GRAPHIC | tm2225310d1-px_phibrobw.jpg | GRAPHIC | 1094794
| Complete submission text file | 0001104659-22-100863.txt |  | 3643424

Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Filer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-36410 | Film No.: 221248521
SIC: 2834 Pharmaceutical Preparations